- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00260546
An-Art Study: Atrioventricular (AV) Node Ablation in Cardiac Resynchronisation Therapy
An-Art Study: AV-Node Ablation in Cardiac Resynchronisation Therapy
Cardiac resynchronisation therapy (CRT) is a highly effective treatment option for patients with symptomatic heart failure and electrical intraventricular dyssynchrony, who are unresponsive to medical therapy. CRT has been shown to improve the quality of life in these patients and lately two studies had shown a mortality reduction with and without the adjunct of an implantable cardioverter defibrillator (ICD). Unfortunately, up to 25% of the CRT recipients do not show a symptomatic improvement after device implantation ("non-responder"). Because of possible intermittent tachycardiac intrinsic conduction, it remains difficult in numerous patients to assure a 100% biventricular stimulation as the prerequisite for a beneficial therapeutic effect. In a important study by Knight et al it could be shown that in a population of 440 CRT-patients, 36% did not have continuous biventricular stimulation. The main cause was the occurrence of atrial tachyarrhythmias, in particular atrial fibrillation. The medical control of rapid ventricular conduction remains a difficult problem in heart failure patients. Furthermore it is unknown how many patients have good biventricular pacing under resting conditions but develop an improved AV-conduction with exercise. This can cause inhibition of ventricular stimulation or in many cases fusion beats. Conversely, an AV-interval programmed too short may have detrimental effects on diastolic filling times.
The safest method to control the ventricular rate and prevent ventricular fusion beats with a normal AV time is the AV node ablation using radiofrequency ablation.
The An Art Study investigates whether patients with an implanted CRT pacemaker or a CRT defibrillator will benefit from an AV-node-ablation using a combined symptomatic heart failure endpoint and duration of biventricular stimulation as compared to a CRT control group.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Early Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients who had a CRT pacemaker or CRT-ICD implanted and who are under optimal medical therapy, can be included 3 months after implantation of the device.
Exclusion Criteria:
- The sole exclusion criterion is no consent of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of biventricular stimulated heart cycles
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Combined endpoint of worsening of heart failure, NYHA class, 6-minute walking distance, and hospitalisation for heart failure, death or heart transplantation
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christian Sticherling, M.D., University Hospital Basel, Cardiology
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 159/05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
ELA Medical, Inc.Approved for marketing
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
Clinical Trials on AV-node ablation
-
Eastbourne General HospitalUnknownPersistent Atrial FibrillationUnited Kingdom
-
Heart and Diabetes Center North-Rhine WestfaliaCompletedAtrial Fibrillation | AV Node Ablation | Escape; RhythmGermany
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonNot yet recruitingHeart Failure | Atrial FibrillationUnited Kingdom
-
Habib KhanLondon Health Sciences CentreRecruitingHeart Failure | Atrial Fibrillation | CardiomyopathiesCanada
-
Region SkaneRecruitingAtrial Fibrillation | Left Atrial DilatationSweden
-
University Medical Centre LjubljanaRecruitingHeart Failure | Atrial Fibrillation | Tachycardia-induced CardiomyopathyCroatia, Austria, Belgium, Bulgaria, Romania, Slovenia
-
Medtronic BRCCompletedAtrial FibrillationGermany, Italy, Sweden
-
Eastbourne General HospitalCompletedPersistent Atrial FibrillationUnited Kingdom
-
University of AdelaideBoston Scientific Corporation; Medtronic; Abbott Medical DevicesCompletedHeart Failure | Atrial FibrillationAustralia, United Kingdom, New Zealand, Malaysia, Germany
-
Centro Prevenzione Malattie Cardiovascolari N....UnknownPermanent Atrial FibrillationItaly